Restless legs syndrome (RLS) is a neurological condition that creates an uncomfortable, irresistible urge to move the legs, particularly at night. Research over the past decade suggests that people with restless legs syndrome may face a higher risk of developing cognitive decline and dementia, though the relationship is not yet fully understood. One 2022 study following over 8,000 older adults found that those with RLS were 50% more likely to develop mild cognitive impairment over a 3-year period compared to people without the condition.
The connection appears to stem from multiple factors: RLS severely disrupts sleep quality, which is critical for memory consolidation and neurological repair. Additionally, the same neurological pathways and dopamine systems affected in RLS also play central roles in cognitive function and Alzheimer’s disease development. For caregivers and individuals concerned about dementia risk, understanding this connection is important—not because RLS guarantees cognitive decline, but because treating RLS aggressively may help protect brain health.
Table of Contents
- What Causes Restless Legs Syndrome and Why Does It Matter for Brain Health?
- How Sleep Disruption from RLS Accelerates Brain Aging
- Distinguishing RLS Symptoms from Early Dementia Signs
- Medical Strategies for Managing RLS and Protecting Cognition
- The Augmentation Risk and Long-Term Cognitive Consequences
- Iron, Ferritin, and Cognitive Resilience
- Neurological Evaluation and Monitoring for Dementia Risk
What Causes Restless Legs Syndrome and Why Does It Matter for Brain Health?
Restless legs syndrome occurs when the brain’s dopamine regulation goes awry, particularly in the basal ganglia, the region that coordinates movement and reward signaling. The exact cause remains unclear, but genetics, iron deficiency, kidney disease, and certain medications all contribute. When dopamine levels are insufficient or dopamine receptors don’t respond properly, the brain sends faulty signals that create the maddening sensation of needing to move—a sensation that improves temporarily once movement begins, only to return.
The brain regions damaged in RLS overlap significantly with those affected early in Alzheimer’s disease and Lewy body dementia. A person with RLS who also has iron deficiency faces compounded risk because iron is essential for myelin formation and mitochondrial function—both critical for neuron survival and cognitive processing. For example, a 68-year-old with lifelong RLS and low ferritin levels (the iron storage marker) has double the incentive to bring ferritin into the normal range, because correcting iron status can both improve RLS symptoms and potentially slow cognitive aging.
How Sleep Disruption from RLS Accelerates Brain Aging
Restless legs syndrome is fundamentally a sleep-stealing condition. People with moderate to severe RLS experience dozens of micro-arousals per night—moments when the leg urge forces them awake or into light sleep, preventing the deep, consolidated sleep stages where the brain clears toxic proteins. During deep sleep, the glymphatic system, a waste-removal mechanism unique to the brain, becomes active and flushes out amyloid-beta and tau—the pathological proteins that accumulate in Alzheimer’s disease.
A patient who sleeps only 5 interrupted hours per night due to RLS loses roughly 15–20 hours of consolidated deep sleep per week compared to a healthy sleeper. Over years, this chronic sleep deprivation has measurable consequences: accelerated cortical atrophy, reduced hippocampal volume, and elevated cerebrospinal fluid amyloid-beta. The limitation here is important: sleep disruption alone does not cause dementia, but it is a modifiable risk factor. Even partial improvement in RLS-related sleep fragmentation—reducing nightly arousals from 40 to 20, for instance—can meaningfully improve sleep quality and potentially slow cognitive decline.
Distinguishing RLS Symptoms from Early Dementia Signs
Early dementia often includes restlessness, agitation, and nighttime wandering, which can be mistaken for or confused with RLS. However, RLS has a specific hallmark: the irresistible need to move is relieved by movement, whereas dementia-related restlessness is not. An 75-year-old woman with RLS will feel the uncomfortable leg sensation worsen as she sits at dinner and immediately improve once she stands and walks; a person with early Alzheimer’s may wander or pace at night due to confusion or disorientation, but movement does not satisfy a specific urge.
The two conditions can coexist, complicating diagnosis. A person with both RLS and mild cognitive impairment may experience severe nighttime disruption that worsens their cognitive symptoms—what appears to be rapid dementia progression may partially reflect the compounding effect of untreated RLS. This is why neurological evaluation is essential: clarifying whether restlessness stems from RLS, dementia-related confusion, or both changes the treatment approach entirely.
Medical Strategies for Managing RLS and Protecting Cognition
First-line treatment for RLS typically involves iron supplementation if ferritin is low (target ferritin above 100 ng/mL for RLS patients), combined with lifestyle modifications like avoiding caffeine, alcohol, and sedating antihistamines, which worsen RLS symptoms. If these measures fail, dopamine agonists—medications like pramipexole or ropinirole—directly address the dopamine deficit. Dopamine agonists are effective for RLS and, importantly, do not impair cognition; however, they can lose effectiveness over time (a phenomenon called augmentation), and they require careful dosing to avoid impulse-control side effects.
A comparison: gabapentin, an alternative treatment, works differently by reducing neuronal excitability rather than boosting dopamine. For older adults with cognitive concerns, gabapentin may be safer than dopamine agonists because it carries no augmentation risk and does not interact with memory systems the same way. The tradeoff is that gabapentin can cause dizziness and confusion in some people, particularly at higher doses, so it requires careful titration. The key point is that RLS is treatable, and effective treatment—whether iron, dopamine agonists, or gabapentin—will improve sleep and may slow cognitive decline.
The Augmentation Risk and Long-Term Cognitive Consequences
One critical limitation of dopamine agonist therapy is augmentation: over months or years, the same dose becomes less effective, and patients need higher doses to control symptoms. Higher doses of dopamine agonists increase the risk of impulse-control disorders (gambling, compulsive spending) and may amplify the dopamine dysregulation that contributes to cognitive decline in the first place.
A patient started on pramipexole 0.25 mg nightly might need 1.5 mg nightly within two years, and at that dose, the cognitive risk profile shifts. For someone with dementia risk factors (family history, previous cognitive decline, or existing mild cognitive impairment), augmentation is a serious concern. This is why regular reassessment is essential: if augmentation occurs, switching to gabapentin or increasing iron treatment may be necessary, rather than simply raising the dopamine agonist dose indefinitely.
Iron, Ferritin, and Cognitive Resilience
Iron deficiency is implicated in roughly 30–50% of RLS cases and is also independently associated with cognitive decline. Iron is essential for the production of myelin, the insulation around axons that speeds nerve conduction, and for cytochrome c oxidase, a critical enzyme in mitochondrial energy production. Without adequate iron, neurons work less efficiently and accumulate damage faster.
Testing should include both serum iron and ferritin; ferritin below 75 ng/mL warrants supplementation, and for RLS patients, ferritin ideally reaches 100–150 ng/mL. Some patients tolerate oral iron poorly (constipation, nausea), in which case intravenous iron infusion, though more invasive, provides faster and more predictable results. A 72-year-old with RLS, ferritin of 40, and subjective cognitive complaints who receives a single IV iron infusion may experience RLS improvement within weeks and, potentially, a slowing of cognitive aging.
Neurological Evaluation and Monitoring for Dementia Risk
Any older adult with RLS should undergo baseline cognitive assessment—at minimum, a Montreal Cognitive Assessment (MoCA) or Mini-Cog screening—to establish cognitive baseline before RLS treatment begins. This allows distinction between cognitive changes due to RLS-related sleep deprivation and cognitive changes stemming from underlying neurodegeneration. For those with RLS and a family history of dementia, annual cognitive rescreening is reasonable.
Similarly, sleep studies may reveal not only RLS but also sleep apnea or periodic limb movements unrelated to RLS discomfort, each of which independently accelerates cognitive decline. A patient whose RLS is severe enough to warrant medication should also have periodic ferritin and renal function checked, because iron and kidney status influence both RLS progression and cognitive aging. Treatment efficacy is measured not only by RLS symptom improvement but by sleep quality (total uninterrupted hours) and cognitive stability (no decline on rescreening within 12 months).
